- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02825706
Educational Physiotherapy in Haemophilia
Effectiveness of an Educational Physiotherapy and Home Exercises Program in Adult Patients With Hemophilia: A Randomized Clinical Trial
Although arthropathy is a serious problem in patients with hemophilia due to the associated morbidity and incapacity, to the best of the investigators knowledge, no studies have looked at the effect of educational physiotherapy for its clinical improvement.
This contribution presents the results of educational physiotherapy program applied for 15 weeks with home exercises - in patients with hemophilic arthropathy. After treatment, experimental group showed improved a significant reduction of pain, and best quality of life al illness behaviour. During treatment no patient showed elbow haemarthrosis, which underlines the safety of this physiotherapy program.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients diagnosed with hemophilia A or B
- Patients over 18 years
- Patients with hemophilic arthropathy with at least 1 involved joint (elbow, knee or ankle)
- having signed the informed consent document.
Exclusion Criteria:
- Patients diagnosed with other congenital bleeding disorders (i.e. von Willebrand disease)
- Patients who developed antibodies to FVIII or FIX (inhibitors)
- Those not able to ambulate as a result of hemophilic arthropathy or any other disability
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental group
The patients in experimental group received 60-minute educational sessions every two weeks about the pathophysiology of hemophilia, clinical manifestations, postural advice and prevention advice to avoid recurrent bleeding.
Likewise, doubts on the clinical progress of hemophilic arthropathy, functional limitations and management of joint pain were resolved.
In parallel with the educational sessions, patients followed a 15-week home exercise program performed once a day, 6 days a week.
The program included muscle stretching exercises; isometric exercises; proprioceptive exercises on one leg with visual support; and a 20-minute walk.
Low-intensity exercises with 20-25 repetitions were included.
|
20 patients with hemophilia were randomly allocated to an educational intervention or to a control group.
The educational intervention was performed every two weeks during 15-week and home exercises were performed once a day, 6 days a week, in the same time
|
No Intervention: Control group
The patients in the control group did not receive any educational sessions and did no exercise at all at home.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline physical condition of joints after treatment and at 6 months
Time Frame: Screening visit, within the first seven days after treatment and after six months follow-up visit
|
The physical condition of joints was assessed using the Gilbert scale that measures swelling, muscle atrophy, joint crepitus, range of motion, axial deformity and instability.
Scores range from 0 to 12 (0 represents no joint injury and 12 represents maximum joint deterioration).
|
Screening visit, within the first seven days after treatment and after six months follow-up visit
|
Change from baseline joint pain after treatment and at 6 months
Time Frame: Screening visit, within the first seven days after treatment and after six months follow-up visit
|
Joint pain was assessed using the Visual Analog Scale (VAS), with scores ranging from 0 (no pain at all) to 10 (the worst pain imaginable by the patient).
|
Screening visit, within the first seven days after treatment and after six months follow-up visit
|
Change from baseline perception of the quality of life after treatment and at 6 months
Time Frame: Screening visit, within the first seven days after treatment and after six months follow-up visit
|
The Haemophilia A-36 questionnaire was used to assess the perception of the quality of life.
This questionnaire consists of 36 items that assess 9 domains (physical health, daily activities, joint damage and pain, treatment satisfaction, treatment difficulties, emotional functioning, mental health and social relationships).
|
Screening visit, within the first seven days after treatment and after six months follow-up visit
|
Change from baseline illness behavior after treatment and at 6 months
Time Frame: Screening visit, within the first seven days after treatment and after six months follow-up visit
|
To assess illness behavior, patients completed the Illness Behavior Questionnaire (IBQ).
This scale consists of 62 items and 8 domains (hypochondriasis, disease conviction, psychological vs. somatic perception of illness, affective inhibition, affective disturbance, denial and irritability).
|
Screening visit, within the first seven days after treatment and after six months follow-up visit
|
Change from baseline frequency of bleedings after treatment and at 6 months
Time Frame: Screening visit, within the first seven days after treatment and after six months follow-up visit
|
The frequency of bleeding is measured with a record which complete the patients, where they indicate the incidence of hematomas and hemarthrosis during the treatment and follow-up.
|
Screening visit, within the first seven days after treatment and after six months follow-up visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Radiological joint deterioration
Time Frame: Screening visit
|
All patients had an assessment of radiological joint deterioration using the Pettersson scale.
This scale, with scores ranging from 0 (a normal joint) to 13 (maximum joint deterioration), is the most widely used to assess joint degeneration produced by hemophilic arthropathy.
The evaluation of radiological joint damage was done at the beginning of the study.
|
Screening visit
|
Age
Time Frame: Screening visit
|
Age of patients included in the study
|
Screening visit
|
Weight
Time Frame: Screening visit
|
Weight of the patients
|
Screening visit
|
Height
Time Frame: Screening visit
|
Height of patients
|
Screening visit
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EducationalPhys
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Haemophilia
-
Al-Azhar UniversityActive, not recruiting
-
University of ValenciaUnknown
-
Novo Nordisk A/SCompletedHaemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia BFrance, United States, India, Mexico, United Kingdom, Netherlands, Sweden, Korea, Republic of, Spain, Switzerland, Serbia, Turkey, Bulgaria, Italy, Japan, Poland, South Africa, Croatia, Algeria, Australia, Bosnia and Herzegovina, ... and more
-
Novo Nordisk A/SCompletedEpidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries (HAEMOcare)Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia BIndia, Morocco, South Africa, Oman
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia BSpain
-
Investigación en Hemofilia y FisioterapiaCompleted
-
Novo Nordisk A/SWithdrawnHealthy | Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B | Relatives to/Carers of PatientsSpain, Canada, United Kingdom
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia BUnited States
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B | Relatives to/Carers of PatientsBrazil
Clinical Trials on Educational physiotherapy group
-
Istanbul Medipol University HospitalNot yet recruitingPhysiotherapy | Educational Problems | Chest PhysiotherapyTurkey
-
Universidad Católica San Antonio de MurciaCompleted
-
Hacettepe UniversityCompletedMultiple Sclerosis | Gait Disorders, Neurologic
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Hasan Kalyoncu UniversityCompleted
-
Universidade Cidade de Sao PauloUnknown
-
CHU de ReimsTerminatedSubacromial Impingement of the ShoulderFrance
-
Nigde Omer Halisdemir UniversityCompleted
-
Tehran University of Medical SciencesCompletedCovid19 | Coronavirus Disease 2019Iran, Islamic Republic of
-
Riphah International UniversityCompletedChronic StrokePakistan